Skip to content
Search our Site
Search our site
Search our site
My PD Journey
Measurement and diagnosis
About the EPDA
Political affairs and policy
All research papers
Measurement and diagnosis
Search research papers
Resources and publications
Measurement and diagnosis research papers
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
The study cohort provides a valuable resource for biomarker discovery and validation in PD. Clinical data and biospecimens, available through The Michael J. Fox Foundation for Parkinson's Research and the National Institute of Neurological Disorders and Stroke, can serve as a platform for discovering biomarkers in clinically typical PD and comparisons across PD's broad and heterogeneous spectrum.
26 April 2016
Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease
GMV reductions in the frontal-limbic-temporal regions were main features of cognitive decline in PD. Unilateral-to-bilateral development of GMV reduction in the frontal-limbic-temporal regions is a possible indicator for PD-MCI to PDD progression, whereas significant hippocampal GMV reduction may not be a marker for early cognitive decline in PD.
25 April 2016
How stable are Parkinson's disease subtypes in de novo patients: Analysis of the PPMI cohort?
Conclusions: TD versus PIGD subtype classification has substantial variability over first year in PD de novo cohort specifically for PIGD subtype. Dopaminergic therapy does not impact the change of the PD subtype. This instability has to be taken into consideration specifically when establishing correlations with the biomarkers and for long term prognostication.
23 April 2016
Aberrant nigral diffusion in Parkinson's disease: A longitudinal diffusion tensor imaging study
Region-of-interest analysis demonstrated that at baseline, PD patients and controls did not differ in regard to diffusion indices in any region assessed. A significant difference of nigral fractional anisotropy and mean diffusivity between controls and PD patients at follow-up was detected and confirmed with longitudinal analysis within PD patients. Alterations in striatal regions were not detected in either group or over time.
22 April 2016
Patterns of Cortical Thinning in Nondemented Parkinson's Disease Patients
Conclusions: Three cortical atrophy subtypes were identified in nondemented Parkinson's disease patients: (1) parieto-temporal pattern of atrophy with worse cognitive performance, (2) occipital and frontal cortical atrophy and younger disease onset, and (3) patients without detectable cortical atrophy. These findings may help identify prognosis markers in Parkinson's disease.
20 April 2016
Time on timing: Dissociating premature responding from interval sensitivity in Parkinson's disease
In this study, 18 PD patients and 19 age-matched controls completed 2 temporal discrimination tasks (bisection and trisection) and a baseline reaction-time task. Timing sensitivity and decision-making processes were quantified by response and response time. An extended version of the modified difference model was used to examine the precision of time representation and the modulation of response time by stimulus ambiguity.
19 April 2016
Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease
Results 8 MoCA items with high item discrimination and appropriate difficulty were identified for use in a short form (s-MoCA). The s-MoCA was highly correlated with the original MoCA, showed robust diagnostic classification and cross-validation procedures substantiated these items.
12 April 2016
Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease
Study data show an association between increased phosphorylation of α-synuclein and the abnormal EEG signatures of cognitive decline. Results suggest that quantitative EEG may provide an in vivo approximation of phosphorylated α-synuclein in PD cortex. This adds to previous evidence that quantitative EEG measures can be considered valid biomarkers of PD cognitive decline.
08 April 2016
Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers
Conclusion: The CSF protein profile differs in LRRK2-associated PD and idiopathic PD, suggesting that pathophysiological mechanisms different from IPD underlie LRRK2-associated PD. Cerebrospinal fluid biomarkers did not prove helpful in differentiating asymptomatic LRRK2 mutation carriers from noncarriers.
04 April 2016
Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease
These results suggest that electroencephalographic slowing during sleep is a new promising predictive biomarker for Parkinson's disease dementia, perhaps as a marker of cholinergic denervation.
01 April 2016
Back to Top
Add page to PDF basket
Copyright © 2016 EPDA. All Rights Reserved.
Privacy and cookies